Genito-urinary Cancer Dataset & Biorepository

Clinical Dataset With Corresponding Samples and Molecular Data

Oncologists at the University of Utah have created a biorepository with corresponding clinical and molecular data focused on genito-urinary malignancies including prostate cancer, kidney cancer, and bladder cancer (testicular cancer planned). This data and sample set can help lead to the identification of nucleic acid, proteomic, lipidomic, metabolomic, and other biomarkers that can be used for prognostication and monitoring of drug response as well as supporting other aspects of the oncology drug development process.

Patient samples are collected serially at three time points:

1. Initial collection prior to starting a new drug (baseline)

2. Follow-up collection three months after treatment initiation

3. Final sample collected at the time of disease progression

Please contact us for more information or to explore potential collaboration opportunities.

Enrollment - Current: 540 patients Target: 1,500 patients

Samples include whole blood, tumor, and other tissues (urine samples pending)

Three samples collected serially over the course of treatment

Design & Development

• All samples collected under CLIA-CAP certified protocols and stored at -80° C within 2 hours of collection to ensure sample quality and to minimize potential contamination. 
• Whole blood samples will allow for germline DNA, cell free DNA, and cell free RNA extractions. PAXgeen collections are also available for cell-based transcriptomic studies.
• Protease inhibitor cocktails included for proteomic studies
• Metabolomic and lipidomic studies planned or available for partnership opportunities

Jason Young
(801) 587-0519
jason.r.young@utah.edu